Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Porsche cuts 2025 outlook as China sales slump; Shares fall

(Sharecast News) - Porsche on Wednesday slashed its 2025 outlook, citing ongoing problems in China and falling electric vehicle demand globally. The luxury German automaker, part of the Volkswagen group, said total sales last year fell 1% to €40.1bn, while operating slumped by 23% to €5.6bn. Sales in China fell by almost a third in 2024. Porsche warned its 2025 margin would hit only 10-12% in light of reduced vehicle sales and an increase in expenses.

It expects revenue to hit €39bn - 40bn this year and a medium-term return on sales of between 15% and 17%, compared with a previous target of 19%. The revised guidance did not factor in 25% tariffs threatened by US President Donald Trump.

Porsche said it would assess whether to pass on any tariff costs to consumers, but it hoped a "sensible" levy regime would be negotiated.

Shares in the company fell 5% in Frankfurt.

"In view of the changed circumstances, we have adjusted our product strategy in all segments," said chief executive Oliver Blume.

The company also said it would undertake a major rescaling of operations that would impact the bottom line with new investment in new models, software and batteries. It warned market conditions would stay "very challenging and for competition in China to intensify".

Porsche in February said it would invest €800m into combustion engine and hybrid cars this year in a pivot away from electric vehicles. It also slashed jobs to bolster its balance sheet.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.